Organization Announcements

Organization Announcements


Paul G. Allen Frontiers Group [to 16 Jan 2021]
No new digest content identified.


BARDA – U.S. Department of HHS [to 16 Jan 2021]
January 12, 2021: HHS, DOD purchase additional doses of Regeneron’s antibody therapeutic to treat patients with mild to moderate COVID-19

January 11, 2021: HHS Launches Web-Based Locator for COVID-19 Outpatient Treatment Sites for Monoclonal Antibodies


BMGF – Gates Foundation [to 16 Jan 2021]
Press Releases and Statements
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 16 Jan 2021]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 16 Jan 2021]
No new digest content identified.


Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 16 Jan 2021]
No new digest content identified.


CEPI – Coalition for Epidemic Preparedness Innovations [to 16 Jan 2021]
Latest News
The importance of blood markers in assessing vaccine efficacy
13 Jan 2021
By Mario Christodoulou


EDCTP [to 16 Jan 2021]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
13 January 2021
Public consultation: Global Roadmap for research and development for TB vaccines
EDCTP has commissioned the Amsterdam Institute for Global Health and Development (AIGHD) to develop a Global Roadmap for research and development for tuberculosis (TB) vaccines. The Roadmap intents to provide global stakeholders such as researchers, funders, industry, regulatory and policy decision makers with key actionable priorities that could help guide their actions. It lists both the short-term objectives as well as the long-term strategic objectives for global TB vaccine development, and focuses on developing and delivering affordable and effective vaccines for use in low- and middle-income countries where the vast majority of people affected by TB are concentrated.

AIGHD and EDCTP invite researchers and stakeholders, as well as everyone who has been involved in the roadmap development process to respond to a public consultation and express their views on aspects of the draft Roadmap before a final version is published.

This is part of the process for developing this Roadmap, which consists of several steps:
:: Desk review and stakeholder inventory
:: In-depth interviews with selected stakeholders
:: A consensus workshop and various rounds of stakeholder consultation on the subsequent draft versions of the Roadmap.

These rounds of consultation included both targeted requests for feedback to selected stakeholders and the current public consultation. The contributions will be published on the AIGHD website (in cases consent was provided) and will be used to complete the final version of the Roadmap.

Draft Roadmap and online form
Draft global roadmap for research and development for tuberculosis vaccines (PDF)
Background document which summarizes the state-of-the-art in research and development for new vaccines for tuberculosis for a TB Vaccine Research & Development Roadmap (PDF).
Contribute to this consultation by filling in the on-line survey.


Emory Vaccine Center [to 16 Jan 2021]
Vaccine Center News
No new digest content identified.


European Medicines Agency [to 16 Jan 2021]
News & Press Releases
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 January 2021
News 15/01/2021
First monthly summary safety report for COVID-19 vaccine Comirnaty
[See COVID – EMA above for detail]



News: EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
Last updated: 12/01/2021


European Vaccine Initiative [to 16 Jan 2021]
Latest News
McKinsey & Company awarded subcontract by EVI
13 Jan 2021
The European Vaccine Initiative (EVI) has selected McKinsey & Company to develop a business plan, including suitable governance structure and financing strategy, that can guide the establishment of a sustainable infrastructure for European vaccine research. Subcontracting McKinsey & Company adds valuable business experience and will be advantageous to the conceptual and technical design of a European vaccine infrastructure. The sub-contract is awarded as part of the project TRANSVAC-DS, Design study for a European vaccine infrastructure, which is funded by the European Commission and comprises a consortium of twenty-five partners from eleven European countries and includes leading academic and other organisations working in areas related to vaccine development…


FDA [to 16 Jan 2021]
Press Announcements /Selected Details
January 15, 2021 – Coronavirus (COVID-19) Update: January 15, 2021
:: Today, the FDA issued and immediately implemented a new guidance entitled, “Protecting Participants in Bioequivalence Studies for Abbreviated New Drug Applications During the COVID-19 Public Health Emergency.” This guidance assists prospective applicants of abbreviated new drug applications (ANDAs) on ensuring participants are protected when resuming or initiating bioequivalence studies conducted to support the approval of an ANDA that has been disrupted during the COVID-19 public health emergency.

January 12, 2021 – FDA Releases Artificial Intelligence/Machine Learning Action Plan
“This action plan outlines the FDA’s next steps towards furthering oversight for AI/ML-based SaMD,” said Bakul Patel, director of the Digital Health Center of Excellence in the Center for Devices and Radiological Health (CDRH). “The plan outlines a holistic approach based on total product lifecycle oversight to further the enormous potential that these technologies have to improve patient care while delivering safe and effective software functionality that improves the quality of care that patients receive. To stay current and address patient safety and improve access to these promising technologies, we anticipate that this action plan will continue to evolve over time.”


FDA – COVID-19 Vaccines [to 16 Jan 2021]
News and Updates; Upcoming Events
I’m a disabled woman of color. Here’s how I overcame my fear of receiving a COVID vaccineExternal Link Disclaimer
An FDA staff member discusses how her former hesitancy and fear grew into hope and a willingness to receive a COVID-19 vaccine.


Fondation Merieux [to 16 Jan 2021]
News, Events
Mérieux Foundation co-organized event
ADVA – Managing the severely ill dengue patients: adults & children
January 20, 2021 – 12:00pm – 3:30pm (CET) Webinar
Co-organized by Asia Dengue Voice & Action Group (ADVA), GDAC, Mérieux Foundation, ISNTD and SEAMEO in support of the 5th Asia Dengue Summit, this webinar is the first in a series titled “Decimate Dengue: The 5th ADS Pre-Summit Webinars”, aimed at bridging the dengue healthcare and research communities via an online platform that allows for closer interaction, learning and adoption of the latest dengue management strategies in the run-up to the 5th Asia Dengue Summit 2022.


Gavi [to 16 Jan 2021]
News releases
500,000 doses of Ebola vaccine to be made available to countries for outbreak response
12 Jan 2021
:: A Gavi-funded global emergency stockpile of Ebola vaccines will be accessible to all countries following a procurement process concluded by UNICEF
:: Seth Berkley: “The accelerated development of the Ebola vaccine was possible thanks to a first-of-its-kind agreement between Gavi and the vaccine manufacturer, which set a precedent for fast-tracking development and production of vaccines against COVID-19”
:: The new Ebola vaccine played an important role in ending the Ebola outbreak in the eastern part of the Democratic Republic of the Congo (DRC), which was officially declared over in June last year. The stockpile is an example of how Gavi, the Vaccine Alliance and UNICEF are strengthening the world’s defenses against potentially devastating infectious disease outbreaks


GHIT Fund [to 16 Jan 2021]
GHIT was set up in 212 with the aim of developing new tools to tackle infectious diseases that
Press Releases
No new digest content identified.


Global Fund [to 16 Jan 2021]
Global Fund signs a record-breaking $8.54 billion in grants to fight HIV, TB and malaria
12 January 2021
In 2020, the Global Fund signed 157 grants for a total of US$8.54 billion for lifesaving HIV, TB and malaria programs and to strengthen systems for health. This is the highest amount of grants ever signed in a single year by the Global Fund. The grants will begin implementation this month.


Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 16 Jan 2021]
No new digest content identified.


Hilleman Laboratories [to 16 Jan 2021]
No new digest content identified.


Human Vaccines Project [to 16 Jan 2021]
Press Releases
Issue 24: Can Changing COVID Vaccine Regimens End the Pandemic Faster?
Jan 15, 2021
…Recently, there was also discussion among U.S. scientists and the company Moderna about cutting the two doses of their mRNA vaccine in half for people ages 18-55 in an effort to double the available doses. This suggestion was based on data from earlier stage clinical trials of this vaccine.
For now, the U.S. Food and Drug Administration (FDA) is opposed to any changes to the dosing regimens. In a statement issued on January 4th, the agency, which granted an Emergency Use Authorization to both the Pfizer/BioNtech and Moderna mRNA COVID-19 vaccines in December, said that altering the dose, reducing the number of doses, or extending the time between doses of these vaccines are reasonable questions to consider and evaluate in clinical trials. “However, at this time, suggesting changes to the FDA-authorized dosing or schedules of these vaccines is premature and not rooted solidly in available evidence.” The AstraZeneca vaccine has not been submitted to the FDA yet for authorization, however, it was authorized already in the U.K., India, and other countries.
But others argue that these strategies to free up more vaccine are warranted given the terrifying course of the pandemic. “As long as there is a shortage of vaccine, protection of the largest number of people against death and disability in the shortest time should take priority over formalism and insufficiency of conclusive data,” says Stanley Plotkin, veteran vaccine developer, Emeritus Professor of Pediatrics at the University of Pennsylvania, and founding board chair of the Human Vaccines Project. “This is an emergency, not a time to stick to routine rules.”
Furthermore, Plotkin argues that there is actually an immunological benefit to delaying vaccine doses. “The optional delay for non-live vaccines is four to six months,” he says…


IAVI [to 16 Jan 2021]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.



International Generic and Biosimilar Medicines Association [IGBA]
Sudarshan Jain takes over the position of IGBA Chair (January 2021)
Geneva, 11 January 2021 – IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), is taking over the position of IGBA Chair for 2021 from Hanan Sboul, Secretary General of the Jordanian Association of Pharmaceutical Manufacturers.



Press Releases/Announcements
No new digest content identified.


IFRC [to 16 Jan 2021]
Selected Press Releases, Announcements
Americas, Honduras
Red Cross: Providing services and protection to migrants in Central America is a humanitarian imperative
Panama/Geneva, 15 January 2021 – The Red Cross is preparing to provide humanitarian assistance to migrants ready to depart Honduras for Guatemala as part of a ‘migrant caravan’. More than 4,000 thousand people are expected to join the caravan that will …
15 January 2021

Armenia, Azerbaijan, Europe, Georgia
New study finds coronavirus has left older people poorer, sicker and more alone
Budapest/Geneva, 13 January 2021 – The COVID-19 pandemic is having catastrophic health, social and financial impacts on older people in Europe’s South Caucasus region, according to a new study led by the International Federation of Red Cross and Red Cr …
13 January 2021

UNICEF, WHO, IFRC and MSF announce the establishment of a global Ebola vaccine stockpile
NEW YORK/ GENEVA, 12 JANUARY 2021: The four leading international health and humanitarian organizations announced today the establishment of a global Ebola vaccine stockpile to ensure outbreak response. The effort to establish the stockpile was led by …
12 January 2021

COVID-19: Vaccines alone will not end pandemic, warns IFRC
Geneva, 11 January 2021 – With COVID-19 vaccines rolling out across many countries, the world’s largest humanitarian network is once again warning that vaccines alone will not end the pandemic. People need to remain vigilant and continue to adhere to b …
… Emanuele Capobianco, IFRC’s Director of Health, said: “We are very concerned about this convergence of a potential false sense of security due to the rollout of vaccines, the emergence of new variants, and the impact of holiday-season travel. Our first line of defence against the virus remains our individual behaviour. Beyond this, the ability of Governments to take swift actions based on scientific evidence is also key to slowing down the pandemic. “Vaccines will help, but unless we all remain vigilant, and unless their deployment is accelerated across the world in a fair and equitable manner, the entire world remains at risk.”


Institut Pasteur [to 16 Jan 2021]
Press documents
No new digest content identified.


IRC International Rescue Committee [to 16 Jan 2021]
Media highlights [Selected]
Press Release
Billions will not receive a COVID-19 vaccine in 2021
January 12, 2021
:: Shortages of COVID-19 vaccines, coupled with vaccine nationalism, means the majority of people in crisis and conflict-affected contexts will not receive a COVID-19 vaccine this year.
:: Investments must be made immediately to strengthen health systems, including shoring up supply chains, allocating sustainable and adequate financing, and empowering community and frontline health workers to ensure no one is left behind.
:: Efforts must also be focused on continuing routine immunizations – in addition to preparation for the COVID-19 vaccines – to protect hard-won gains and avoid the spread of other vaccine-preventable disease outbreaks.

Press Release
24 million Yemenis at catastrophic humanitarian risk following new U.S. terrorist designations of Ansar Allah, warns IRC
January 11, 2021


IVAC [to 16 Jan 2021]
Updates; Events
No new digest content identified.


IVI [to 16 Jan 2021]
Selected IVI News, Announcements, Events
No new digest content identified.


JEE Alliance [to 16 Jan 2021]
Selected News and Events
No new digest content identified.


Johns Hopkins Center for Health Security [to 16 Jan 2021]
Center News
No new digest content identified.


MSF/Médecins Sans Frontières [to 16 Jan 2021]
Latest [Selected Announcements]
MSF teams ramp up support as violence escalates

Providing assistance to people in Ethiopia and Sudan in wake of Tigray violence

Responding to the second wave of COVID-19 in Switzerland


National Vaccine Program Office – U.S. HHS [to 16 Jan 2021]
Upcoming Meetings/Latest Updates
No new digest content identified.


NIH [to 16 Jan 2021]
News Releases
NIH scientists identify nutrient that helps prevent bacterial infection
January 15, 2021 — Taurine, which helps the body digest fats and oils, could offer treatment benefit.


PATH [to 16 Jan 2021]
Press Release
No new digest content identified


Sabin Vaccine Institute [to 16 Jan 2021]
Statements and Press Releases
Sabin Vaccine Institute Funds Researchers to Investigate COVID-19 Misinformation, Design Solutions to Increase Vaccine Acceptance
Wednesday, January 13, 2021
, D.C. – The Sabin Vaccine Institute (Sabin) announced today that it has awarded grants to research teams in four countries to explore the social drivers of COVID-19 misinformation, and its impact on routine immunization acceptance and the acceptance of a COVID-19 vaccine.
The grants are part of Sabin’s Social and Behavioral Interventions for Vaccination Acceptance Small Grants Program, which provides funding to researchers in low- and middle-income countries to better understand the social drivers of vaccination and design small-scale interventions to assess their impact on vaccination acceptance.
Five research teams in India, Kenya, Pakistan and Uganda will receive up to $30,000 to conduct this research and pilot a small-scale intervention in their respective communities over a period of 10 months…


UNAIDS [to 16 Jan 2021]
Selected Press Releases/Reports/Statements
12 January 2021
Vulnerability mapping to help sex workers in Bangladesh and Myanmar

11 January 2021
Attaining UNAIDS’ proposed societal and legal barrier targets could stop 440 000 AIDS-related deaths


UNICEF [to 16 Jan 2021]
Selected Press releases, Statements
Statement  01/12/2021
Children cannot afford another year of school disruption
Statement by UNICEF Executive Director Henrietta Fore

Press release  01/11/2021
UNICEF, WHO, IFRC and MSF announce the establishment of a global Ebola vaccine stockpile
[See Milestones above for detail]


Unitaid [to 16 Jan 2021]
Featured News
12 JANUARY 2021
Unitaid funding sees launch of world’s first long-acting medicines centre at University of Liverpool
Geneva – Efforts to revolutionise treatments for debilitating infectious diseases have been amplified today with the launch of a new research centre at the University of Liverpool.
Established as part of a US$40 million international research consortium, primarily funded by Unitaid, the University of Liverpool’s Centre of Excellence for Long-acting Therapeutics (CELT) will be the first of its kind in the world.
By repurposing existing medicines into slow-release formulations, where drug effectiveness can be sustained over several months, ‘long-acting’ technology has already been successfully implemented in the fields of contraception and schizophrenia.
It now has the potential to improve the outcomes for treatment and prevention of deadly diseases such as HIV, malaria, Hepatitis C and tuberculosis, which particularly impact low- and middle-income countries.
Current treatment courses for these conditions have often resulted in poor outcomes in low-resource environments, as those living with diseases struggle with regimens that can involve taking dozens of tablets every day and rely on regular access to healthcare settings.
CELT’s mission is to broaden knowledge of long-acting medicines and disseminate key research, with the aim of revolutionising how these devastating diseases are treated, particularly in countries where access to healthcare is challenging…


Vaccination Acceptance Research Network (VARN) [to 16 Jan 2021]
No new digest content identified.


Vaccine Confidence Project [to 16 Jan 2021]
News, Research and Reports
15 Jan 2021
CONVINCE (COVID New Vaccine Information, Communication and Engagement)
Vaccine Literacy: Building Public Support for a COVID-19 vaccine
Call to Action from Wilton Park, City University of New York (CUNY) Graduate School of Public Health & Health Policy and the Vaccine Confidence Project at the London School of Hygiene and Tropical Medicine
Effective communication to prepare a ‘vaccine literate’ public and persuade policymakers to trust the science and embrace new vaccines for COVID-19 as they become available must begin now.
To ensure a COVID-19 vaccine is accepted, we must invest in:
:: a multi-sectoral commitment to develop trust in vaccines
:: preparation of accurate and convincing information sources about vaccines
:: innovative multi-media and interpersonal approaches to communicate and engage with all audiences..


Vaccine Education Center – Children’s Hospital of Philadelphia [to 16 Jan 2021]
No new digest content identified.


Wellcome Trust [to 16 Jan 2021]
Explainer | 13 January 2021
What drugs are working as treatments for Covid-19?
From existing antivirals to new antibody therapies – researchers are working at incredible speed to find the best drugs to treat Covid-19.


The Wistar Institute [to 16 Jan 2021]
Press Releases
Jan. 13, 2021
New Insights Into the Control of Inflammation 
The EGR1 transcription factor has distinct roles in early and late macrophage maturation stages, blunting macrophage activation and inflammation.

Press Release 
Jan. 12, 2021
Wistar Researchers Develop New Humanized Mouse Model That Provides Insight Into Immunotherapy Resistance
Tumor-infiltrating mast cells are connected to immune checkpoint inhibitor resistance in melanoma.

Press Release 
Jan. 11, 2021
Wistar Scientists Discover Link Between a Genetic Driver of Ovarian Cancer and Metabolism, Opening the Way for New Therapeutic Strategies
Loss of ARID1A causes increased glutamine metabolism, which can be blocked pharmacologically to target ARID1A-mutant tumors.


WFPHA: World Federation of Public Health Associations [to 16 Jan 2021]
Latest News
Norwegian Perspectives on Immunization: A Positive Response to Public Health Advocacy during COVID-19
Jan 14, 2021
Throughout the COVID-19 pandemic, health inequity has become increasingly apparent. The public health workforce has rapidly mobilized to advocate…

Building Confidence in COVID-19 Vaccination
Jan 13, 2021
The COVID-19 vaccines bring the promise of a global rescue from the coronavirus pandemic; however, building people’s confidence in these new vaccines seems to be a herculean task. Myths and misinformation…


World Organisation for Animal Health (OIE) [to 16 Jan 2021]
No new digest content identified.





ARM [Alliance for Regenerative Medicine] [to 16 Jan 2021]
Press Releases – Alliance for Regenerative Medicine (
Press Releases
No new digest content identified.


BIO [to 16 Jan 2021]
Press Releases
BIO Releases Statement Concerning Future Political Giving
January 11, 2021
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on BIO’s political contributions:   “As of today BIO will be pausing our political giving so we can…


DCVMN – Developing Country Vaccine Manufacturers Network [to 16 Jan 2021]
News; Upcoming events
No new digest content identified.


ICBA – International Council of Biotechnology Associations [to 16 Jan 2021]
No new digest content identified.


IFPMA [to 16 Jan 2021]
Selected Press Releases, Statements, Publications
Innovative biopharmaceutical industry comment on COVID-19 vaccines dosing strategies and recommend following the science
13 January 2021
[See COVID above for full text]

Speak Up Africa and IFPMA start their search for winners of the Africa Young Innovators
12 January 2021

Pharma innovation delivers COVID-19 solutions beyond expectations, but calls for the dilution of intellectual property
08 December 2020
…despite a lack of any evidence, there have been claims that intellectual property (IP) rights are hindering the response to the pandemic. A waiver proposal currently being discussed by the World Trade Organization (WTO) is looking to suspend Member States’ obligations to protect innovator’s intellectual property assets that are critical to tackle the COVID-19 pandemic. In view of the progress made so far in providing COVID-19 solutions and the partnerships in place to boost research and scale-up manufacturing of vaccines and treatments, diluting national and international IP frameworks during this pandemic is counterproductive. It will not lead to faster research and development or access, but it will undermine confidence in what has proven to be a well-functioning IP system, allowing industry to partner with confidence with academia, research institutes, foundations and other private companies, significantly expediting the research and development of medicines to address the worlds’ many unmet medical needs…


PhRMA [to 16 Jan 2021]
Selected Press Releases, Statements
Innovative Biopharmaceutical Industry Comment on COVID-19 Vaccines Dosing Strategies and Recommend Following the Science
January 13, 2021
This statement on COVID-19 vaccine dosing strategies was issued by the Pharmaceutical Research and Manufacturers of America (PhRMA), the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA),  the International Council of Biotech Associations (ICBA), the Biotechnology Innovation Organization (BIO), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Vaccines Europe.
[See COVID above for full text]

PhRMA Statement on Political Giving
January 12, 2021
Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl released the following statement regarding violent protests in Washington D.C. and the organization’s decision on political giving.

Paper finds gaps in health data are a barrier to health equity
January 11, 2021
COVID-19 has laid bare racial disparities in the United States health system. For example, COVID-19 cases among Native Hawaiian/Pacific Islanders are up to 2.5 times higher as compared to whites. Similarly, the rate of COVID-19 related deaths among Black Americans and American Indian/Alaskan Natives are twice as high as whites. A recent PhRMA paper finds that gaps in information on race, ethnicity and health are barriers to achieving health equity for many groups…
PhRMA has decided to address these issues head on and will support others willing to do the same. Read our first paper in the series, “Gaps in Available Data Exacerbate Health Disparities and Create Barriers to Change.”
Emily Donald